Stockreport

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Crinetics Pharmaceuticals, Inc.  (CRNX) 
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm Check Earnings Report
PDF CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the n [Read more]